Physician profile
Ke Ning
NPI 1073802674
$8,708.65
in general payments reported to CMS, 2019-2025
50 companies · $3,599 in 2025
The $3,599 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2021: $11.92 · 2022: $86.61 · 2023: $2,623 · 2024: $1,623 · 2025: $3,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,640 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,639.79 |
| Education | $205.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,435.78 | 2023-2025 | Cabometyx |
| Janssen Biotech, INC. | $621.29 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $603.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $489.82 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Celgene Corporation | $475.99 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $451.44 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $404.92 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $334.48 | 2019-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $272.43 | 2019-2025 | Padcev, Xospata, Vyloy |
| Astrazeneca Pharmaceuticals Lp | $254.43 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Regeneron Healthcare Solutions, INC. | $239.47 | 2024-2025 | Libtayo, Lynozyfic |
| Genzyme Corporation | $226.11 | 2019-2025 | |
| Glaxosmithkline, LLC. | $216.24 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $208.55 | 2024-2025 | |
| Gilead Sciences, INC. | $191.89 | 2021-2025 | Trodelvy |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $147.95 | 2019-2025 | Fruzaqla, Hyqvia, Vpriv |
| Seagen INC. | $140.49 | 2019-2025 | Padcev |
| Intuitive Surgical, INC. | $134.62 | 2025 | |
| Incyte Corporation | $131.29 | 2023-2025 | Monjuvi, Jakafi, Niktimvo |
| Array Biopharma INC | $129.19 | 2025 | Braftovi, Lorbrena, Mektovi |
| Eisai INC. | $126.10 | 2019-2025 | |
| Beigene USA, INC. | $102.74 | 2023-2025 | Brukinsa |
| Taiho Oncology, INC. | $98.72 | 2024-2025 | |
| Genentech USA, INC. | $88.50 | 2019-2023 | Venclexta, Lunsumio |
| Geron Corporation | $88.04 | 2025 | Rytelo |
| Kite Pharma, INC. | $84.49 | 2022-2024 | Yescarta |
| Amgen INC. | $83.83 | 2019-2023 | Lumakras |
| Emd Serono, INC. | $83.00 | 2019-2025 | Bavencio |
| Beone Medicines USA, INC. | $76.54 | 2025 | Brukinsa |
| Sobi, INC | $70.50 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $57.30 | 2025 | Onivyde |
| Tersera Therapeutics LLC | $55.76 | 2023-2025 | Quzyttir |
| Bayer Healthcare Pharmaceuticals INC. | $55.57 | 2019-2025 | |
| Puma Biotechnology, INC. | $54.91 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $54.47 | 2022-2023 | Rezlidhia, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.43 | 2019-2025 | Gilotrif |
| Tesaro, INC. | $43.84 | 2019 | |
| Genmab U.S., INC. | $42.25 | 2024-2025 | Epkinly |
| Myriad Genetic Laboratories, INC. | $41.77 | 2025 | Myrisk |
| Aveo Pharmaceuticals, INC. | $35.07 | 2024-2025 | |
| Iovance Biotherapeutics, INC. | $32.29 | 2025 | Amtagvi |
| Immunocore Limited | $30.26 | 2025 | Kimmtrak |
| Mirati Therapeutics, INC. | $23.56 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $20.04 | 2025 | Monoferric |
| Jazz Pharmaceuticals INC. | $19.83 | 2024 | |
| Alexion Pharmaceuticals, INC. | $16.46 | 2024 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $16.09 | 2019 | |
| Novocure INC. | $16.01 | 2025 | Optune Lua (Novottf-200t) |
| Karyopharm Therapeutics INC. | $14.73 | 2024 | Xpovio |
| Lilly USA, LLC | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ke Ning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.